A p53 drug response signature identifies prognostic genes in high-risk neuroblastoma.
Chemotherapy induces apoptosis and tumor regression primarily through activation of p53-mediated transcription. Neuroblastoma is a p53 wild type malignancy at diagnosis and repression of p53 signaling plays an important role in its pathogenesis. Recently developed small molecule inhibitors of the MD...
Main Authors: | Eveline Barbieri, Katleen De Preter, Mario Capasso, Peter Johansson, Tsz-Kwong Man, Zaowen Chen, Paris Stowers, Gian Paolo Tonini, Frank Speleman, Jason M Shohet |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3865347?pdf=render |
Similar Items
-
Mdm2 Deficiency Suppresses MYCN-Driven Neuroblastoma Tumorigenesis In Vivo
by: Zaowen Chen, et al.
Published: (2009-08-01) -
Mechanisms of p53-mediated apoptosis in neuroblastoma
by: Barbieri, Eveline <1973>
Published: (2010) -
A 6-gene signature identifies four molecular subgroups of neuroblastoma
by: Kogner Per, et al.
Published: (2011-04-01) -
Establishment and Validation of a Prognostic Immune Signature in Neuroblastoma
by: Yunhu Yu, et al.
Published: (2021-08-01) -
Development and Validation of an RNA-Seq-Based Prognostic Signature in Neuroblastoma
by: Jian-Guo Zhou, et al.
Published: (2019-12-01)